Keytruda Expands Cervical Cancer Position With ESMO Data

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

In addition to securing a key position in first-line disease, Keytruda has potential to expand its presence in later lines with combination data from Seagen/Genmab’s Tivdak.

3d illustration of T cells attacking a cancer cell
Merck presented data at ESMO on Keytruda in first-line cervical cancer • Source: Shutterstock

Data released at the European Society for Medical Oncology (ESMO) on Merck & Co., Inc.’s Keytruda strengthen the PD-1 inhibitor drug’s leading position in cervical cancer as the company moves the drug into the first-line setting. But Seagen Inc.  and Genmab A/S’s newly approved antibody-drug conjugate (ADC) Tivdak (tisotumab vedotin-tftv) means increased competition in the second-line setting of a cancer that affects a small population.

Roche Holding AG’s Avastin (bevacizumab) plus platinum chemotherapy had been the standard of care, but the field is seeing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

What To Look Out For At ESMO 2024

 
• By Alexandra Shimmings

Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.  

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 
• By Andrew McConaghie

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

More from Anticancer

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Ordspono Will Be Regeneron’s First Independent European Launch

 
• By Jessica Merrill

Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.